Hepatitis B and C in dialysis units in Iran: Changing the epidemiology

Hemodialysis International

Volumn 12, Issue 3, 2008, Pages 378-382

  Alavian, Seyed Moayed ^a   Bagheri Lankarani, Kamran ^b   Mahdavi Mazdeh, Mitra ^c,d   Nourozi, Shahram ^d  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d Center for Transplantation and Special Diseases   (Iran)

Author keywords

Developing world; Hemodialysis; Hepatitis B; Hepatitis C; Iran

Indexed keywords

ARTICLE; CHRONIC KIDNEY FAILURE; DISEASE TRANSMISSION; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; INCIDENCE; IRAN; MALE; MIDDLE AGED; PREVALENCE; RECYCLING; RENAL REPLACEMENT THERAPY; STATISTICS;

EQUIPMENT REUSE; FEMALE; HEPATITIS B; HEPATITIS C; HUMANS; INCIDENCE; IRAN; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PREVALENCE; RENAL DIALYSIS;

EID: 55949105772     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2008.00284.x     Document Type: Article

References (40)

1. Fabrizi F, Bunnapradist S, Lunghi G, Aucella F, Martin P. Epidemiology and clinical significance of hepatotropic infections in dialysis patients. Minerva Urol Nephrol. 2004; 56:249-257.
2. Alavian SM, Adibi P, Zali MR. Heptitis C virus in Iran: Epidemiology of an emerging infection. Arch Iranian Med. 2005; 8:84-90.
3. Hosseini-Moghaddam S, Keyvani H, Kasiri H, et al. Distribution of Hepatitis C virus genotypes among hemodialysis patients in Tehran: A multicenter study. J Med Virol. 2006; 78:569-573.
4. Alavian SM, Einollahi B, Hajarizadeh B, Bakhtiari S, Nafar N, Ahrabi S. Prevalence of hepatitis C virus infection and related risk factors among Iranian haemodialysis patients. Nephrology. 2003; 8:256-260.
5. Fabrizi F, Lunghi G, Martin P. Hepatitis B virus infection in hemodialysis: Recent discoveries. J Nephrol. 2002; 15:463-468.
6. Amiri ZM, Shakib AJ, Toorchi M. Seroprevalence of hepatitis C and risk factors in haemodialysis patients in Guilan, Iran. East Mediterr Health J. 2005; 11:372-376.
7. Ansar MM, Kooloobandi A. Prevalence of hepatitis C virus infection in thalassemia and haemodialysis patients in North Iran-Rasht. J Viral Hepatitis. 2002; 9:390-392.
8. Alavian SM, Ardeshiri A, Hajarizadeh B. Seroprevalence of anti-HCV Ab among Iranian hemophilia patients. Transfus Today. 2001; 49:4-5.
9. Alavian SM, Einollahi B, Hajarizadeh B, Bakhtiari S, Nafar M, Ahrabi S. Prevalence of hepatitis C virus infection and related risk factors among Iranian hemodialysis patients. Nephrology. 2003; 8:256-260.
10. Alavian SM, Gholami B, Masarrat S. Hepatitis C risk factors in Iranian volunteer blood donors, a case control study. J Gastroenterol Hepatol. 2002; 17:1092-1097.
11. Ramezani A, Eslamifar A, Banifazl M, et al. Efficacy and long-term immunogenicity of hepatitis B vaccine in haemodialysis patients. Int J Clin Pract. 2007; Nov 12 [Epub ahead of print].
12. Malekzadeh R, Khatibian M, Rezvan H. Viral hepatitis in the world and Iran. J Iranian Med Council. 1997; 15:183- 200.
13. Saneie-Moghadam E, Khosravi S, Salehi M, Khaleghi Moghadam M, Ghasri M, Yaghoobnejad-Moghadam Z. Studing RPR, anti-HIV, and HBsAg in rejected blood donors with history of cupping (Hejamat). 11th Iranian Congress of Infectious Disease and Tropical Medicine, Tehran, Iran, Feb 24-28, 2003; 179.
14. Mirmomen SH, Alavian SM, Hajarizadeh B, et al. Epidemiology of hepatitis B, hepatitis C, and human immunodeficiency virus infections in patients with betathalassemia in Iran: A multicenter study. Arch Iranian Med. 2006; 9:319-323.
15. Bozergi SH, Ahmadzad Asl M, Ramazani H, Kargarfard H, Alavian SM. Study of viral infections prevalence in blood donors of Qazvin province in different time intervals and during Bam earthquake. Govaresh. 2007; 11:242-248.
16. Alavian SM. Control of hepatitis C in Iran: Vision and Missions. Hepatitis Monthly. 2007; 7:57-58.
17. Alavian SM, Hajarizadeh B. Remarkable difference in the mode of HCV transmission among haemodialysis patients and IVDAs. Gut. 2004; 7:1057.
18. Mahdavi-Mazdeh M, Zamyadi M, Nafar M. Assessment of management and treatment response in hemodialysis patients in Tehran province, Iran. Nephrol Dial Transplant. 2008; 23:288-293.
19. Mahdavi-Mazdeh M, Heidary Rouchi A, Norouzi Sh, Aghighi M, Rajolani H, Ahrabi S. Renal replacement therapy in Iran. Urol J. 2007; 4:66-70.
20. El-Amin HH, Osman EM, Mekki MO, et al. Hepatitis C virus infection in hemodialysis parients in Sudan: Two centers report. Saudi J Kidney Dis Transplant. 2007; 18:101-106.
21. Karkar A. Hepatitis C in dialysis units: The Saudi experience. Hemodial Int. 2007; 11:354-367.
22. Yakaryilmaz F, Gurbuz O, Guliter S, et al. Prevalence of occult hepatitis B and hepatitis C virus infections in Turkish hemodialysis patients. Renal Failure. 2006; 28:729-735.
23. Sulowicz W, Radziszewski A, Chowaniec E. Hepatitis C virus infection in dialysis patients. Hemodial Int. 2007; 11:286-295.
24. Carneiro M, Teles SH, Lampe E, et al. Molecular and epidemiological study on nosocomial transmission of HCV in hemodialysis patients in Brazil. J Med Virol. 2007; 79:1325-1333.
25. Chlabicz S, Flisiak R, Grzeszczuk A, Kovalczuk O, Prokopowicz D, Chyczewski L. Known and probable risk factors for hepatitis C infection: A case series in North-Eastern Poland. World J Gastroenterol. 2006; 12:141- 145.
26. Baril G, Traver JA. Decrease in the hepatitis C virus (HCV) prevalence in hemodialysis patients in Spain: Effect of time, initiating HCV prevalence studies and adoption of isolation measures. Antivir Res. 2003; 60:129-134.
27. Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH. Hepatitis C and renal disease: An update. Am J Kidney Dis. 2003; 42:631-657.
28. Einolahi B, Hajarizadeh B, Bakhtiari S, et al. Pre-transplant hepatitis C virus infection and its effect on the posttransplant course of living renal allograft recipients. J Gastroenterol Hepatol. 2003; 18:836-840.
29. Gallego E, Lopez A, Perez J, et al. Effect of isolation measures on the incidence and prevalence of hepatitis C virus infection in hemodialysis. Nephron Clin Pract. 2006; 104:C1-C6.
30. Saxena Ak, Panhotra BR, Sundaram DS, et al. Impact of dedicated space, dialysis equipment, and nursing staff on the transmission of hepatitis C virus in a hemodialysis unite of the Middle East. Am J Infect Control. 2003; 31:26-33.
31. Alavian SM, Fallahian F, Bagheri Lankarani K. The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis. 2007; 16:403-406.
32. Kabir A, Alavian SM, Keyvani H. Distribution of hepatitis C virus genotypes in patients infected by different sources and its correlation with clinical and virological parameters: A preliminary study. Comp Hepatol. 2006; 5:4.
33. De Mitri MS, Poussin K, Baccarini P, et al. HCV-associated liver cancer without cirrhosis. Lancet. 1995; 345:413-415.
34. Zein NN. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev. 2000; 13:223-235.
35. Samimi-Rad K, Nategh R, Malekzadeh R, Norder H, Magnius L. Molecular epidemiology of hepatitis C virus in Iran as reflected by phylogenetic analysis of the NS5B region. J Med Virol. 2004; 74:246-252.
36. Nguyen MH, Keeffe EB. Epidemiology and treatment outcomes of patients with chronic hepatitis C and genotypes to 9. Rev Gastroenterol Disord. 2004; 41:S14-S21.
37. Re V, Lampe E, Yoshida CF, et al. Hepatitis C virus genotypes in Cordoba, Argentina. Unexpected high prevalence of genotype 2. Medicina (B Aires). 2003; 63:205- 210.
38. Maluf DG, Fisher RA, King AL, et al. Hepatitis C virus infection and kidney transplantation: Predictors of patient and graft survival. Transplantation. 2007; 83:853- 857.
39. Fabrizi F, Bunnapradist S, Lunghi G, Martin P. Transplantation of kidneys from HCV-positive donors: A safe strategy? J Nephrol. 2003; 16:617.
40. Mahmoud IM, Elhabashi AF, Elsawy E, El-Husseini AA, Sheha GE, Sobh MA. The impact of hepatitis C virus viremia on renal graft and patient survival: A 9-year prospective study. Am J Kidney Dis. 2004; 43:131-139.